Oral Mucositis Market

Rising prevalence of head and neck cancer is driving the market growth

Market CAGR for oral mucositis is being driven by the rising cases of head and neck cancer. About 150,000 and 750,000 Head and Neck Cancer instances are reported yearly, respectively, in the U.S. and Europe. In between 60 and 70 percent of these patients, severe oral mucositis (SOM) will occur. Radiation and cytotoxic chemotherapy medications have the side effect of causing oral mucositis. According to National Institutes of Health, over 400,000 people in the US are estimated to receive an oral mucositis diagnosis each year. The market for oral mucositis therapies is expanding alongside the worldwide cancer patient population.

Oral mucositis therapy is becoming increasingly necessary, driving the market growth.

The development of collaborative tactics and increased clinical trials are improving the pipeline of oral mucositis treatments. The oral mucositis therapies pipeline included more than twenty medications in various stages of research as of March 2019 (in addition to nine commercialized treatments). The Phase 3 DOM-INNATE study for SGX942 (dusquetide) for the treatment of oral mucositis (OM) in patients with head and neck cancer (HNC) was completed in June 2020 by Soligenix, Inc., a biopharmaceutical company that develops and markets medications to treat rare diseases. Top-line results are anticipated in the fourth quarter of 2020 once enrollment is complete.

demand for diagnostic tools has increased due to an increasing number of programs launched by different organizations to enhance awareness about malignant tumor screening. During the research period, industry growth is anticipated to be boosted by partnerships and collaborations launched by the National Cervical Cancer Coalition, the WHO, the CDC, and the U.S. Preventive Services Task Force to increase cervical cancer screening. Additionally, several nations have taken action to increase screening for early screening and assist the current sufferers. For patients who need aid during treatment, the Indian government established Ayushman Bharat and the Prime Minister's National Relief Fund.

Thus, driving the oral mucositis market revenue.

The Global Oral Mucositis Market Industry is projected to experience substantial growth over the coming years. With an estimated market value of 0.61 USD Billion in 2024, it is expected to reach 1.23 USD Billion by 2035. This growth trajectory, characterized by a CAGR of 6.56% from 2025 to 2035, highlights the increasing recognition of oral mucositis as a significant complication of cancer therapies. The market dynamics are influenced by various factors, including advancements in treatment options, rising awareness, and supportive government policies.

The increasing prevalence of cancer globally is a primary driver for the Global Oral Mucositis Market Industry. As cancer treatments, particularly chemotherapy and radiotherapy, are widely adopted, the incidence of oral mucositis as a side effect is expected to rise. In 2024, the market is projected to reach 0.61 USD Billion, reflecting the growing need for effective management solutions. This trend indicates a significant demand for products aimed at alleviating the symptoms associated with oral mucositis, thereby enhancing patient quality of life during cancer treatment.

Supportive government policies and initiatives aimed at improving cancer care are fostering growth in the Global Oral Mucositis Market Industry. Governments are increasingly recognizing the need for comprehensive cancer management strategies, which include addressing the side effects of treatments such as oral mucositis. Funding for research and development, along with regulatory support for new therapies, is likely to enhance market dynamics. This supportive environment may contribute to the anticipated growth trajectory, as stakeholders in the healthcare sector align their efforts with public health objectives.

Growing awareness and education regarding oral mucositis among healthcare professionals and patients are crucial drivers for the Global Oral Mucositis Market Industry. Initiatives aimed at educating stakeholders about the condition's impact and management strategies are becoming more prevalent. This heightened awareness is likely to lead to earlier diagnosis and treatment, thereby improving patient outcomes. As a result, the market is expected to expand significantly, with projections indicating a rise to 1.23 USD Billion by 2035, underscoring the importance of education in addressing this condition.

Innovations in treatment modalities for oral mucositis are propelling the Global Oral Mucositis Market Industry forward. New therapeutic approaches, including biologics and targeted therapies, are being developed to mitigate the effects of oral mucositis. These advancements not only improve patient outcomes but also expand the range of treatment options available. As the market evolves, the introduction of novel therapies is anticipated to contribute to a compound annual growth rate (CAGR) of 6.56% from 2025 to 2035, indicating a robust growth trajectory driven by enhanced treatment efficacy.

Emerging markets and demographic shifts are influencing the Global Oral Mucositis Market Industry. As populations in developing regions grow and age, the incidence of cancer and related complications, including oral mucositis, is expected to rise. This demographic trend presents significant opportunities for market expansion, particularly in regions where healthcare infrastructure is improving. The increasing focus on cancer treatment in these markets is likely to drive demand for oral mucositis management solutions, further contributing to the overall growth of the industry.

By region, the report offers market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American oral mucositis market area will dominate this market. An increase in head and neck cancer incidence will be the key factor driving the severe oral mucositis market's growth in the US throughout the forecast period. The 2021 report from the American Society of Clinical Oncology (ASCO) estimated that 66,630 people (48,740 men and 17,890 women) would be diagnosed with head and neck cancer.

Additionally, throughout the forecast period, top players' focus on inorganic strategies and capital raising are predicted to be important drivers of market advancement.

Further, the leading countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2: ORAL MUCOSITIS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe’s oral mucositis market accounts for the second-largest market share. The rising incidence of cancer cases, expanding government backing, and expanded research activities to create cutting-edge medical treatment are driving the market in the region. Increased research and development efforts for creating fresh treatments for oral mucositis and technological advancements in biopharmaceuticals are other factors influencing the expansion of the market. Further, the German oral mucositis market held the largest market share, and the UK oral mucositis market was the rapidly-growing market in the European region.

The Asia-Pacific Oral Mucositis Market is estimated to expand at a rapid rate from 2024 to 2032. Due to factors like increasing prevalence, a sizable patient pool, proposed product launches, government support, improved healthcare infrastructure, increased awareness, an increase in well-equipped hospitals, increased research & development activities, technological advancements, and growing investments by market players for the creation of targeted therapies, thus, it is anticipated that growth would occur most quickly in the Asia-Pacific area. Moreover, China’s oral mucositis market held the largest market share, and the Indian oral mucositis market was the rapidly-growing market in the Asia-Pacific region.

Leading market players are largely investing in research and development to expand their product lines, which will help the oral mucositis market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The oral mucositis industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the oral mucositis industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the oral mucositis industry has stipulated some of the most important medicinal benefits. Major players in the oral mucositis market, including Himalaya Drug Company, Innovation Pharmaceuticals, AMAG Pharmaceutical Inc, Shoreline Pharmaceuticals Inc, Izun Pharmaceuticals Corporation, and others, are funding operations for research and development to boost market demand.

EVERSANA is a creator and operator of an integrated and independent commercial services platform that addresses life science price, access, reimbursement, adherence, and product delivery concerns. The company provides pharmaceutical companies with clinical trial recruiting, extensive patient support, and drug safety, consulting, and management services. In March 2023, Eversana partnered with ChemoMouthpiece to help the latter's medical gadget for oncology patients' US launch and commercialization. The Chemo Mouthpiece is an intraoral ice pack that assists cancer patients in managing and treating oral mucositis. The gadget is intended to administer cryotherapy to the oral cavity of chemotherapy patients.

Sinopia is a biotechnology startup that aims to identify and advance novel therapies by leveraging a multi-omics-powered artificial intelligence/machine learning drug discovery platform. The company's platform enables high-throughput screening and profiling by bridging in vitro to in vivo translation gaps, and it has successfully uncovered multi-billion dollar therapeutic potential and a novel target for chemo/radiation-induced oral mucositis. In February 2023, Sinopia Biosciences, Inc. was awarded funding from National Institute of Dental and Craniofacial Research, a section of National Institutes of Health in the U.S.A., to fund ongoing research into therapeutic possibilities for treating oral mucositis.